Edgestream Partners L.P. purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,411 shares of the biotechnology company's stock, valued at approximately $1,499,000.
Other hedge funds have also modified their holdings of the company. Callan Family Office LLC purchased a new position in shares of Repligen during the 4th quarter valued at $434,000. Raymond James Financial Inc. bought a new position in shares of Repligen in the fourth quarter worth about $52,492,000. Arizona State Retirement System grew its position in shares of Repligen by 0.8% during the fourth quarter. Arizona State Retirement System now owns 15,410 shares of the biotechnology company's stock worth $2,218,000 after purchasing an additional 126 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in Repligen during the 4th quarter valued at approximately $3,066,000. Finally, Charles Schwab Investment Management Inc. raised its stake in Repligen by 4.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 377,900 shares of the biotechnology company's stock valued at $54,395,000 after purchasing an additional 14,521 shares during the period. 97.64% of the stock is currently owned by institutional investors.
Repligen Stock Up 5.7 %
Repligen stock traded up $8.18 during mid-day trading on Friday, reaching $150.62. 498,479 shares of the company were exchanged, compared to its average volume of 643,822. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a market cap of $8.44 billion, a P/E ratio of -295.33, a PEG ratio of 4.54 and a beta of 0.95. The business has a fifty day moving average of $157.17 and a 200 day moving average of $148.45. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $200.23.
Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on RGEN. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a report on Friday, February 21st. Canaccord Genuity Group increased their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday, February 21st. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price on the stock. Finally, Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $181.00.
Read Our Latest Stock Analysis on Repligen
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Articles
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
